IL-6 is a critical cytokine in acute phase response and involved in the pathogenesis of
several chronic inflammatory diseases including cancer. Studies have highlighted that levels …

Inflammation is at the forefront of carcinogenesis, tumor progression and resistance to
therapy. The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) …

Despite complete resection, cancer recurrence frequently occurs in clinical practice. This
indicates that cancer cells had already metastasized from their organ of origin at the time of …

The therapeutic landscape of lung cancer has expanded significantly over the past decade.
Advancements in molecularly targeted therapies, strategies to discover and treat resistance …

Lung cancer is the leading cause of cancer deaths throughout the world. The majority of
patients are diagnosed with locally advanced or metastatic disease when surgery, the best …

The purpose of this paper is to demonstrate that a Bayesian network (BN) approach can
explore hierarchical biophysical relationships that influence tumor response and predict …

Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer and is a fast
progressive disease when left untreated. Identification of potential biomarkers in NSCLC is …

Abstract Background The Th1 cell-specific transcription factor TBX21 functions as a
regulator of expression of a Th1 cytokine, interferon gamma (IFN-γ). However, the specific …

Introduction A hormonal role in NSCLC development is well documented. We previously
showed that the aromatase inhibitor (AI) anastrozole decreased development of tobacco …

Intratracheal administration of a novel IL-10 formulation suppressed IL-17–driven, CD4+ T
cell–dependent tumorigenesis in the LSL-K-ras G12D murine lung cancer model. Analysis …